Within the last year, one of our type 1 diabetes clinical trials involving an effective cancer drug concluded. Results published in November 2009 in the New England Journal of Medicine (NEJM)shows that anti-CD20 (FDA approved and marketed as Rituxan) has been shown to be effective in new onset diabetes by slowing down the progression of the disease.
It is hard to believe that we are just days away from the end of the decade, and nearly ten years since the founding of the UCSF Diabetes Center. I am grateful for the progress we continue to make toward preventing, treating and ultimately curing diabetes.
The UCSF Center for Vulnerable Populations (CVP) at San Francisco General Hospital (SFGH) continues to receive recognition for its innovative research that advances health communication to prevent and treat chronic diseases in patients at risk.
A new study, Assessing the Value of Diabetes Education, has shown that healthcare costs for the serious consequences of diabetes are significantly lower for people who have been referred to a diabetes education program.
After living with type 1 diabetes for 33 years, Ken Reynolds feels like a new person with a much better quality of life -- thanks to an islet transplant he received at UCSF last January. Diagnosed with diabetes as a child, Ken began to experience severe hypoglycemic unawareness ten years ago.
The body's immune system is supposed to "tolerate" itself and distinguish "self" from "non-self." Autoimmune diseases such as type 1 diabetes result from the breakdown of this system, causing immune cells to attack and destroy insulin-producing beta cells or "self."
Last month, the California Institute of Regenerative Medicine (CIRM) awarded a Diabetes Disease Team Award to Novocell, Inc., a San Diego-based stem cell engineering biotech, and the UCSF Diabetes Center, led by Jeffrey Bluestone, PhD, Michael German, MD, Matthias Hebrok, PhD, and Qizhi Tang, PhD. Called the "dream team" by CIRM working group reviewers, this group's
President Barack Obama awarded stem cell faculty member Jeremy Reiter, MD, PhD a Presidential Early Career Award for Scientists and Engineers. Dr. Reiter was one of twelve awardees selected by the President’s White House Office of Science and Technology.
Thanks to the very generous support of longtime supporters, Bob and Michelle Friend, a new Endowed Chair in the Diabetes Center has been created. Selected as the recipient of the Robert B. Friend and Michelle M. Friend Endowed Chair in Diabetes Research is Mark Anderson, MD, PhD.
When Greg Szot arrived at UCSF nearly a decade ago from the University of Chicago, he was on a mission to accelerate the field of pancreatic islet transplantation to assist those living with type 1 diabetes.
If you are a parent/caregiver of a child with diabetes, the UCSF Pediatric Diabetes Department hopes your child’s return to school this month has gone smoothly. All families are urged to meet with the school nurse and all staff who supervise your child to educate them about your child’s diabetes care needs and establish protocol for delivery of medical orders.
Does someone in your family have type 1 diabetes? If so, other family members may be at risk for developing diabetes. UCSF is offering a free simple blood test for relatives of people with type 1 diabetes. The test could detect an increased risk for type 1 diabetes up to ten years before symptoms appear.
In August, UCSF’s Mary Sullivan, RN, MSN, C-ANP, CDE received the Diabetes Educator of the Year Award at the American Association of Diabetes Educators (AADE) Annual Convention in Atlanta. This national award sponsored by LifeScan, Inc. honors a diabetes educator who has made a special contribution to the field through dedication, innovation and sensitivity in patient care.